For the first time since its inception in 2000, the VISION leadership programme will be held in Australia in February 2020. Targeting current and emerging biotech leaders, VISION provides key leadership insights into the sector trends and skills required to navigate the changing bioindustry landscape.
Leveraging knowledge from across the industry, the course will bring together key executive experts from a range of companies who experience leadership challenges on a day-to-day basis.
These include creating robust intellectual property strategies, portfolio management, nurturing a culture of innovation, managing stringent regulatory requirements and operational limits, dealing with high risk and reward environments and costly timelines while navigating global markets and socio-political landscapes.
Places are limited to 25 delegates to ensure focused discussions, workshops and networking opportunities. Speakers confirmed for 2020 include:
- Barry Buckland, CEO, BiologicB (former VP, Merck)
- Kym Baker, General Manager, Patheon Biologics Australia
- Charles Cooney, Professor, MIT
- Eli Keshavarz-Moore, Professor of Bioprocess Science and Enterprise, UCL
- Trent Munro, Professor, AIBN (former Executive Director, Amgen)
- Chris Nave, Founder and Managing Director, Brandon Capital Partners
- Vicki Salmon, Partner, The IP Asset Partnership
- Rahul Singhvi, COO, Takeda Vaccines
- Neil Weir, CEO, Sitryx Therapeutics Limited (former VP, UCB)
UCL Biochemical Engineering, in collaboration with the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN), will be delivering the VISION Leadership programme in Brisbane from 25 to 28th February 2020.
Visit the VISION webpage for more information and to register your interest.